These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12145269)

  • 41. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential.
    Gromada J; Brock B; Schmitz O; Rorsman P
    Basic Clin Pharmacol Toxicol; 2004 Dec; 95(6):252-62. PubMed ID: 15569269
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use.
    Byrne MM; Göke B
    Diabet Med; 1996 Oct; 13(10):854-60. PubMed ID: 8911778
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effects of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors].
    Fiorentino TV; Sesti G
    G Ital Cardiol (Rome); 2013 Dec; 14(12 Suppl):15-25. PubMed ID: 24362783
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
    Nauck MA; Meier JJ
    Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Significance of combination therapy with an insulin sensitizer and a DPP-4(dipeptidyl peptidase-4) inhibitor].
    Yasuda T; Shimomura I
    Nihon Rinsho; 2013 Mar; 71(3):555-62. PubMed ID: 23631252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
    Madsbad S; Krarup T; Deacon CF; Holst JJ
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):491-9. PubMed ID: 18542012
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass.
    Gallwitz B
    Diabetes Technol Ther; 2005 Aug; 7(4):651-7. PubMed ID: 16120042
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M; Bunck MC; Heine RJ
    Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Addition of incretin therapy to metformin in type 2 diabetes.
    Scheen AJ; Radermecker RP
    Lancet; 2010 Apr; 375(9724):1410-2. PubMed ID: 20417840
    [No Abstract]   [Full Text] [Related]  

  • 52. Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011; 13(3): 193-203.
    Carr RD; Katzeff HL; Alexander CM; Berger JP; Xu SS; Thornberry N
    Diabetes Obes Metab; 2012 Apr; 14(4):383-4. PubMed ID: 22390829
    [No Abstract]   [Full Text] [Related]  

  • 53. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell.
    Mulherin AJ; Oh AH; Kim H; Grieco A; Lauffer LM; Brubaker PL
    Endocrinology; 2011 Dec; 152(12):4610-9. PubMed ID: 21971158
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Management of Type 2 Diabetes: a Practical Approach].
    Donath M
    Praxis (Bern 1994); 2016 Jun; 105(12):699-702. PubMed ID: 27269776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treatment of diabetes mellitus. New developments and hopes].
    Verspohl EJ
    Med Monatsschr Pharm; 2005 Jun; 28(6):193-202; quiz 203. PubMed ID: 15960421
    [No Abstract]   [Full Text] [Related]  

  • 56. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gut-derived incretin hormones and new therapeutic approaches.
    Bloomgarden ZT
    Diabetes Care; 2004 Oct; 27(10):2554-9. PubMed ID: 15451935
    [No Abstract]   [Full Text] [Related]  

  • 58. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.
    Lindsay JR; Duffy NA; McKillop AM; Ardill J; O'Harte FP; Flatt PR; Bell PM
    Diabet Med; 2005 May; 22(5):654-7. PubMed ID: 15842525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.
    Larsen J; Hylleberg B; Ng K; Damsbo P
    Diabetes Care; 2001 Aug; 24(8):1416-21. PubMed ID: 11473079
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [New medications for patients with type 2 diabetes].
    Meillet L
    Soins; 2014 Oct; (789):15-8. PubMed ID: 25518129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.